0.19
-0.0083(-4.09%)
Currency In USD
| Previous Close | 0.2 |
| Open | 0.2 |
| Day High | 0.2 |
| Day Low | 0.19 |
| 52-Week High | 2.03 |
| 52-Week Low | 0.17 |
| Volume | 1.57M |
| Average Volume | 15.82M |
| Market Cap | 6.57M |
| PE | 0.09 |
| EPS | 2.06 |
| Moving Average 50 Days | 0.28 |
| Moving Average 200 Days | 0.57 |
| Change | -0.01 |
If you invested $1000 in Theriva Biologics, Inc. (TOVX) 10 years ago, it would be worth $0.01 as of December 25, 2025 at a share price of $0.195. Whereas If you bought $1000 worth of Theriva Biologics, Inc. (TOVX) shares 5 years ago, it would be worth $2.14 as of December 25, 2025 at a share price of $0.195.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Theriva Biologics Provides Response to Unusual Market Action
GlobeNewswire Inc.
Oct 24, 2025 6:31 PM GMT
ROCKVILLE, Md., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high un
Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds
GlobeNewswire Inc.
Oct 16, 2025 12:11 PM GMT
ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high un
Theriva™ Biologics Announces Upcoming Presentations at Medical Meetings
GlobeNewswire Inc.
Oct 13, 2025 12:00 PM GMT
- VCN-01 expanded mPDAC data from VIRAGE Phase 2b trial to be presented at ESMO 2025 - - SYN-004 Interim blinded safety and pharmacokinetic data to be presented at IDWeek 2025 - Rockville, Md., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (